← Signal Board

Spero Therapeutics financial statements

스페로 테라퓨틱스NASDAQ:SPRO · Nasdaq · Healthcare · sector #17
$1.17-1.68%
2026-10-07 close

Spero Therapeutics's published financial data is dated 2026-10-04. 2024 revenue was $48M. 2024 operating profit was −$73M.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -13.81
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-13.81
Beneish M-Score
8.28

Statistical manipulation-risk signal

Sloan accrual
-40.82%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -49%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (20.7% → -152.9%, -173.6%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-152.9%
Interest coverage
-15.3x
Return on equity (ROE)
-148.7%

Operating margin −5pp

Operating loss
Interest coverageBase -15.3x adverse case -15.8x
Return on equity (ROE)Base -148.7% adverse case -174.7%

Revenue −15%

Interest coverage risk
Interest coverageBase -15.3x adverse case -13x
Return on equity (ROE)Base -148.7% adverse case -145.6%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -15.3x adverse case -12.1x
Return on equity (ROE)Base -148.7% adverse case -172.2%

Interest coverage limit

Already below the limit by 162.9pp

Interest coverage limit at an operating margin of 10%

Interest expense coverage threshold

Spero Therapeutics notifications

Quantus Signal · live data · not investment advice · Privacy Policy